ALMS · XBRL financial data
Alumis financial statements, every fiscal year
The same tables from 2 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (ALMS's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|
| Revenue from contracts with customers | — | 24,050 |
| Research and development | 265,554 | 385,998 |
| General and administrative | 35,200 | 91,856 |
| Total operating expenses | 300,754 | 477,854 |
| Operating income (loss) | (300,754) | (453,804) |
| Other income (expense) | (93) | (169) |
| Income tax expense (benefit) | 0 | (8,561) |
| Net income (loss) | (294,233) | (243,325) |
| Earnings per share, basic USD per share | (10.38) | (2.86) |
| Earnings per share, diluted USD per share | (10.38) | (2.86) |
| Weighted average shares, basic thousands of shares | 28,342 | 85,030 |
| Weighted average shares, diluted thousands of shares | 28,342 | 85,030 |
- † Share count changed about 3x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (ALMS's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|
| Cash and cash equivalents | 169,526 | 89,670 |
| Marketable securities | 118,737 | 218,831 |
| Prepaid and other current assets | 4,501 | 6,740 |
| Total current assets | 306,188 | 318,232 |
| Property and equipment, net | 20,968 | 18,190 |
| Right-of-use asset | 12,723 | 16,971 |
| Total assets | 340,992 | 411,940 |
| Accounts payable | 9,624 | 10,106 |
| Total current liabilities | 50,910 | 73,318 |
| Lease liability, non-current | 29,165 | 32,244 |
| Total liabilities | 80,888 | 110,643 |
| Accumulated deficit | (658,551) | (901,876) |
| Total stockholders' equity | 260,104 | 301,297 |
| Total liabilities and equity | 340,992 | 411,940 |
- † Share count changed about 3x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (ALMS's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|
| Net income (loss) | (294,233) | (243,325) |
| Stock-based compensation | 19,457 | 43,524 |
| Depreciation and amortization | 3,152 | 3,496 |
| Net cash from operating activities | (255,078) | (369,523) |
| Purchases of property and equipment | 1,732 | 653 |
| Net cash from investing activities | (113,790) | 287,877 |
| Share repurchases | 6 | 17 |
| Net cash from financing activities | 492,367 | 2,067 |
- † Share count changed about 3x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Alumis | 63,706 | 1,662 | (81,500)* | not reported | 0.8 quarters | 10-QJun 30, 2026 |
| Crescent Biopharma | 171,593 | 0 | (19,463)* | 37.1M | 8.8 quarters | 10-QJun 30, 2026 |
| Editas Medicine | 181,815 | 11,890 | (29,568)* | 153.6M | 7.2 quarters | 10-QJun 30, 2026 |
| Omeros | 1,988 | 28,529 | 4,149* | 72.4M | — | 10-QJun 30, 2026 |
| Palvella Therapeutics | 187,803 | not reported | (12,845)* | 14.4M | 19.5 quarters | 10-QJun 30, 2026 |
| Lexicon Pharmaceuticals | 40,924 | 692 | (9,192)* | 445.0M | 20.7 quarters | 10-QJun 30, 2026 |
| Esperion Therapeutics | 156,158 | 80,104 | (27,722) | 257.4M | 5.6 quarters | 10-QMar 31, 2026 |
| XOMA Royalty | 85,600 | 12,318 | 6,121 | 12.5M | — | 10-QMar 31, 2026 |
| 4D Molecular Therapeutics | 70,372 | 3,781 | (69,999)* | 55.2M | 5.2 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.